The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
The phase III QuANTUM-R randomized study (NCT02039726) is assessing the efficacy and safety of quizartinib (60 mg, with a 30 mg lead-in for 15 days), an oral, highly potent and selective FLT3 inhibitor, versus salvage chemotherapy (SC) in patients with relapsed or refractory (R/R) fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD)-mutated acute myeloid leukemia (AML). Initial data presented from this study at the 23rd Congress of the European Hematology Association (EHA), Stockholm, Sweden, by Jorge Cortes from The University Texas MD Anderson Cancer Center demonstrated that quizartinib led to a significant reduction in the risk of death by 24% compared to SC in patients with FLT3-ITD-positive R/R AML after first-line treatment with or without hematopoietic stem cell transplantation (HSCT). The final safety and efficacy data from this study were presented by Jorge Cortes at the 60th American Society of Hematology Annual Meeting & Exposition.
Overall, 367 FLT3-ITD AML patients who had R/R disease within 6 months of first remission after standard chemotherapy, were enrolled in this study. Patients were randomized 2:1 to receive quizartinib (n = 245; median age = 55 years; range, 19–81) or investigator’s choice SC (n = 122; median age = 58; range, 18–78). SC choices were low dose cytarabine (LoDAC, n = 29), mitoxantrone, etoposide, and intermediate-dose cytarabine (MEC, n = 40), or fludarabine, cytarabine, and granulocyte-colony stimulating factor with idarubicin (FLAG-IDA, n = 53).
The primary and secondary endpoints were overall survival (OS) and event-free survival (EFS) in the intention-to-treat (ITT) population. The data cut-off for this study was February 2018.
In summary, the final safety and efficacy data from the phase III QuANTUM-R trial demonstrate that quizartinib was well tolerated and significantly prolongs OS in R/R FLT3-ITD AML patients compared to SC. The OS benefit for quizartinib was seen across subgroups and was reproduced consistently across sensitivity analyses.
References